Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study

Sickle Cell Anemia Clinical Trial

Official title:

Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study. Clinical and Genetic Characteristics of Sickle Cell Anemia (SCA) Patients in Three Different Communities.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01905787
• Other study ID #: 0128-11-EMC
• Status: Active, not recruiting
• Start date: January 2012
• Est. completion date: December 31, 2020

Study information

• Verified date: October 2019
• Source: HaEmek Medical Center, Israel
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to take advance of the presence of two different cohorts of SCA patients in one country, the first group included SCA patients from Bedouin Arab origin that lives in Israel for more than one century and originally comes from African countries or Saudi Arabia, those patients lives in north east Israel and are treated at the Hematology Unit of the Emek Medical Center, the second group are SCA patients from African origin that come to Israel in the last decades and belong to original African population, this group receive treatment at the Pediatric Hematology Unit, Dana Children's Hospital, Ichilov Medical Center. A third group is a cohort of SCA patients treated at Schneider Children's Hospital Hematology Unit. Those patients belong also to the Israel Arab population and patients from a village that African Muslims live for many years. The characteristics of the three groups will be compared to the characteristics of a fourth group, a cohort of Afro-American SCA patients that are followed up and treated at the Pediatric Hematology Unit, Detroit Children's Medical Center, Detroit, Michigan, USA.

Description:

Group 1 - Emek group - (EMC): 100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).

Group 2 - Dana group - (DMC): 50 patients will be included in the study. Group 3 - Schneider group - (ShMC): 50 patients will be included in the study. Group 4 - Detroit group - (WYUMC): 100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).

Patients with Sickle cell hemoglobin C (SC) and Sickle cell hemoglobin D (SD) disease will not be included as part of the study analysis due to the small numbers of patients expected, but the investigators are encouraged to report the data of those patients for further analysis.

Age: No age limits, patients can be included since diagnosis till age 40 since teenagers and young adults are often treated at pediatric hematology units.

Gender: Males and Females will be included in the study. Pregnant patients: Pregnancy will not be considered as exclusion criteria. Data about pregnancy under Hydroxyurea treatment both in females and in males should be included, including malformations in the offspring. It needs to be emphasized that the recommendation to the patients in both sexes is to stop Hydroxyurea treatment at last three months before conception.

Data collection: Data will be collected from the medical files. Demographic and family history and laboratory findings at diagnosis will be included.

Genetic mutations of the β globin gene in patients with Sickle Cell β thalassemia will be included if previously analyzed and recorded in medical files. Also α globin mutations and SCA haplotypes will be included if they were previously analyzed and are part of the data already present in the medical files.

Further genetic analysis including β and α globin mutations, haplotypes and xmn1 polymorphism will be included in an extension study but those analysis are not an integral part of this initial study unless they were performed before this present study.

Clinical complaints from the last 10 years will be summarized. Iron chelation and Hydroxyurea treatment given in the last 10 years will be summarized.

Complications that were diagnosed at any age will also be recorded.

Exclusion criteria:

• Patients without sufficient data at the medical files due to lack of regular follow up will be excluded.

• Patients that give explicit refuse in participation.

Inclusion criteria:

• All the patients currently treated and followed up at the centers in Israel will be included.

• A similar number of patients at same age range and same diagnosis will be included from the whole cohort at Detroit MC. Since at Detroit MC a significant larger number of patients, the criteria for patient's selection at this center will be a cohort matched for gender and age to the Israel patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 300
• Est. completion date: December 31, 2020
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 40 Years

Eligibility

Inclusion Criteria:

• All patients followed up in the centers that participate in the study.

• Pregnancy will not be considered as exclusion criteria.

Exclusion Criteria:

• Patients with SC and SD disease will not be included.

Related Conditions & MeSH terms

• Anemia
• Anemia, Sickle Cell
• Sickle Cell Anemia
• Sickle Cell ß+ or ß0 Thalassemia
• Thalassemia

Locations

Country	Name	City	State
Israel	Pediatric Hematology Unit HaEmek Medical Center	Afula
Israel	Pediatric Hematology Unit - Schneider Children's Hospital - Beilinson Medical Center	Petah Tikva
Israel	Pediatric Hematology Unit - Dana Children's Hospital - Ichilov Medical Center	Tel Aviv
United States	Children's Hospital of Michigan, Detroit Medical Center - Wayne State University	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
HaEmek Medical Center, Israel

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Retrospective summary to the response to Hydroxyurea Therapy	From all the groups patients treated by hydroxyurea will be compared between them and between treated patients to patients that did not receive hydroxyurea in terms of clinical events	5 years
Primary	Clinical comparative study between four different Sickle Cell Populations	Clinical events during the observational period including crises, blood transfusions requirements and hospitalizations.	5 years
Secondary	Clinical severity and laboratory results related to the Sickle Cell disease	Laboratory analysis results (Blood count, Hgb F and tests related to hemolysis) will be compared between the different groups	5 years